Company intelligence / Profile preview

Neogenix Oncology, Inc.

Rockville, Maryland or New York, United Statesneogenomics.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Neogenix Oncology was a clinical-stage biotherapeutics company focused on developing novel therapeutic and companion diagnostic products for cancer detection and treatment. Its lead asset was Ensituximab, a monoclonal antibody targeting MUC5AC for colorectal cancer. The company advanced this program into Phase II trials but has not reported recent progress since the early-to-mid 2010s. The company appears inactive/defunct by mid–2020s.

Therapeutic areas: OncologyEndocrinologyGastroenterology
Modalities: monoclonal antibodies
Industry: Biotech

Drug pipeline

3 assets

NEO-101

Phase 1

Indications: Pancreatic cancer, Colorectal cancer

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Neogenix Oncology, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neogenix Oncology, Inc..

Explore the full profile